Innovative Research Award
Rushendhiran Kesavan — UT Southwestern Medical Center, United States
Rushendhiran Kesavan is a researcher affiliated with UT Southwestern Medical Center whose documented scholarly profile includes research activity in renal cancer. The available Scopus metrics identify 16 documents, 639 citations, and an h-index of 11, providing quantitative indicators of publication and citation activity relevant to assessment for an Innovative Research Award. [1]
Abstract
Rushendhiran Kesavan, affiliated with UT Southwestern Medical Center in the United States, is recognized within the research domain of renal cancer. His scholarly profile records 16 Scopus-indexed documents, 639 citations, and an h-index of 11. These indicators provide measurable evidence of research dissemination and scholarly influence. His subject-area association with renal cancer places his work within an important biomedical research field concerned with understanding disease mechanisms, improving diagnostic approaches, and developing more effective therapeutic strategies. The Innovative Research Award provides a framework for recognizing researchers whose scholarly activities demonstrate originality, methodological contribution, and potential relevance to advancing contemporary scientific knowledge and practice. [1]
Keywords
Nanoscience, renal cancer, cancer research, biomedical research, innovative research, translational research, oncology, scientific publications, research impact, scholarly communication. [1]
Introduction
Innovative biomedical research contributes to scientific progress by introducing new concepts, analytical approaches, technologies, and evidence that can improve understanding of complex diseases. Renal cancer remains an important area of oncology research, requiring multidisciplinary investigation across molecular biology, diagnostics, therapeutics, and clinical science. [2]
Research Profile
The available researcher profile identifies Rushendhiran Kesavan with UT Southwestern Medical Center and a primary subject association with renal cancer. The Scopus record lists 16 documents and 639 citations, while the reported h-index of 11 indicates that at least 11 publications have each received 11 or more citations according to the indexed record. [1]
Research Contributions
Research in renal cancer can contribute to the broader understanding of tumor biology, disease progression, molecular characteristics, and therapeutic opportunities. Within this context, Kesavan’s documented research profile provides evidence of scholarly participation in a specialized cancer-research field, while the publication and citation record offers quantitative measures for evaluating the reach of his scientific contributions. [1]
Publications
The Scopus profile associated with Rushendhiran Kesavan records 16 documents. Bibliographic databases such as Scopus provide structured information concerning scholarly publications and citation relationships, enabling researchers and institutions to examine publication activity and research influence through standardized metrics. [3]
Research Impact
The reported 639 citations represent a measurable level of scholarly attention to the researcher’s indexed publications. Citation counts can help contextualize research visibility, although they should be interpreted alongside publication quality, field-specific citation practices, collaboration, and the substantive contribution of individual studies. [4]
Award Suitability
The Innovative Research Award can be considered in relation to Kesavan’s documented research profile because his work is associated with a specialized biomedical field and is supported by measurable publication and citation activity. The available metrics provide relevant evidence for an academic recognition profile, subject to independent verification of the underlying scholarly record. [5]
Conclusion
Rushendhiran Kesavan’s academic profile reflects research activity at UT Southwestern Medical Center with a subject-area focus on renal cancer. The reported Scopus indicators of 16 documents, 639 citations, and an h-index of 11 provide quantitative evidence of scholarly dissemination and impact. [1]
External Links
References
- Elsevier. (n.d.). Scopus author details: Rushendhiran Kesavan, Author ID 55654064000. Scopus.https://www.scopus.com/authid/detail.uri?authorId=55654064000
- Tran, D. H., Kim, D., Kesavan, R., Brown, H., Dey, T., Soflaee, M. H., Vu, H. S., Tasdogan, A., Guo, J., Bezwada, D., Al Saad, H., Cai, F., Solmonson, A., Rion, H., Chabatya, R., Merchant, S., Manales, N. J., Tcheuyap, V. T., Mulkey, M., Mathews, T. P., Brugarolas, J., Morrison, S. J., Zhu, H., DeBerardinis, R. J., & Hoxhaj, G. (2024). De novo and salvage purine synthesis pathways across tissues and tumors. Cell, 187(14), 3602–3618.e20.
https://doi.org/10.1016/j.cell.2024.05.011
-
Tran, D. H., Kesavan, R., Rion, H., Hoseini Soflaee, M., Solmonson, A., Bezwada, D., Vu, H. S., Cai, F., Phillips, J. A., III, DeBerardinis, R. J., & Hoxhaj, G. (2021). Mitochondrial NADP+ is essential for proline biosynthesis during cell growth. Nature Metabolism, 3, 571–585.
https://doi.org/10.1038/s42255-021-00374-y
- Kowshik, J., Giri, H., Kishore, T. K. K., Kesavan, R., Vankudavath, R. N., Reddy, G. B., Dixit, M., & Nagini, S. (2014). Ellagic acid inhibits VEGF/VEGFR2, PI3K/Akt and MAPK signaling cascades in the hamster cheek pouch carcinogenesis model. Anti-Cancer Agents in Medicinal Chemistry, 14(10), 1247–1257.
https://doi.org/10.2174/1871520614666140723114217
-
Soflaee, M. H., Kesavan, R., Sahu, U., Tasdogan, A., Villa, E., Djabari, Z., Cai, F., Tran, D. H., Vu, H. S., Ali, E. S., Rion, H., O’Hara, B. P., Kelekar, S., Hallett, J. H., Martin, M., Mathews, T. P., Gao, P., Asara, J. M., Manning, B. D., Ben-Sahra, I., & Hoxhaj, G. (2022). Purine nucleotide depletion prompts cell migration by stimulating the serine synthesis pathway. Nature Communications, 13, Article 30362.
https://doi.org/10.1038/s41467-022-30362-z